IRON · XBRL financial data

Disc Medicine financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRON's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	28,170	48,717	33,437	69,264	96,671	170,640
Selling, general and administrative	—	—	—	21,861	33,049	65,382
General and administrative	5,870	20,285	14,038	21,861	—	—
Total operating expenses	34,040	69,002	47,475	91,125	129,720	236,022
Operating income (loss)	(34,040)	(69,002)	(47,475)	(91,125)	(129,720)	(236,022)
Interest expense	6,826	2,158	—	0	572	3,607
Other income (expense)	—	(13)	0	(2)	(2)	45
Income tax expense (benefit)	—	—	0	99	355	361
Net income (loss)	(40,837)	(71,869)	(46,827)	(76,429)	(109,357)	(212,184)
Earnings per share, basic USD per share	—	(40.95)	(45.05)	(3.42)	(3.96)	(6.01)
Earnings per share, diluted USD per share	—	(40.95)	(45.05)	(3.42)	(3.96)	(6.01)
Weighted average shares, basic thousands of shares	—	878	1,039	22,316	27,606	35,296
Weighted average shares, diluted thousands of shares	—	878	1,039	22,316	27,606	35,296

Fiscal years (IRON's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,212	136,627	194,611	360,382	192,434	91,145
Marketable securities	—	—	—	0	297,447	700,007
Prepaid and other current assets	—	—	—	5,280	3,734	12,746
Total current assets	1,338	140,100	198,491	365,662	493,615	803,898
Property and equipment, net	294	0	168	170	751	1,159
Right-of-use asset	—	1,641	1,430	1,930	1,569	1,096
Total assets	122,093	140,437	200,205	367,996	496,773	806,879
Accounts payable	5	2,950	16,162	12,629	7,948	9,018
Accrued liabilities	493	4,096	6,109	8,145	8,097	15,561
Current portion of long-term debt	11,689	—	—	—	—	—
Total current liabilities	598	14,834	22,578	21,439	23,316	36,641
Lease liability, non-current	—	1,334	1,027	1,436	1,548	1,253
Total liabilities	4,824	15,596	23,605	22,875	53,186	67,053
Accumulated deficit	(812)	(184,690)	(112,216)	(188,645)	(298,002)	(510,186)
Total stockholders' equity	5,000	124,841	176,600	345,121	443,587	739,826
Total liabilities and equity	122,093	140,437	200,205	367,996	496,773	806,879
Common shares outstanding (cover page) thousands of shares	42,999	43,208	18,998	24,681	34,569	38,160

Fiscal years (IRON's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(40,837)	(71,869)	(46,827)	(76,429)	(109,357)	(212,184)
Stock-based compensation	983	7,787	2,089	5,530	16,815	34,340
Depreciation and amortization	—	32	89	100	156	281
Net cash from operating activities	(32,708)	(59,700)	(42,252)	(73,462)	(93,926)	(180,393)
Purchases of property and equipment	22	71	151	89	505	933
Net cash from investing activities	(22)	344	(151)	(89)	(292,332)	(394,299)
Proceeds from issuing common stock	20,084	0	53,500	0	—	—
Proceeds from long-term debt	—	—	—	0	28,988	0
Net cash from financing activities	34,247	191,480	148,978	239,379	218,314	473,407
Net change in cash	1,517	132,124	106,575	165,828	(167,944)	(101,285)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Disc Medicine	98,676	not reported	(44,201)*	38.4M	16.2 quarters	Q2 FY26 10-QJun 30, 2026
Arrowhead Pharmaceuticals	54,759	75,253	(177,469)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	75,615	83,902	9,605*	161.9M	—	Q3 FY26 10-QSep 30, 2026
Travere Therapeutics	123,542	224,563	98,204*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360,212	266,044	56,669*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47,454	22	(57,410)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	581,394	106,120	41,698*	71.1M	—	Q3 FY26 10-QSep 30, 2026
Ligand Pharmaceuticals	55,958	78,746	(27,591)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	598,641	13,475	(67,272)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.